

**Basingstoke, Southampton and Winchester
District Prescribing Committee (DPC)**

Recommendations of the meeting of Tuesday 10th December 2019

Supported or limited support e.g. Specialist recommendation

Cefazolin Injection (Cefazolin- MIP®) -based on evaluation of the evidence the Committee supports restricted use of cefazolin, when recommended by microbiology/infection control for use only for treatment of MSSA bacteraemia in patients with mild penicillin allergy who are unsuitable for flucloxacillin. Consider adding to formularies as RED.

Fluticasone propionate 400mcg nasal drops suspension (Flixonase nasules®) - the Committee supports the restricted use of fluticasone nasules for the relief of symptoms of severe chronic rhinosinusitis with nasal polyps in adults if control with glucocorticoid sprays is insufficient. This product is unlicensed in children < 16 years. Specialists must communicate indication and intended duration of therapy to primary care prescribers. Consider adding to formularies as AMBER.

Mesalazine 1600mg MR tablet (Octasa®) - this new higher strength of mesalazine tablet is supported for use by the Committee. Consider adding to formularies as GREEN.

Pentosan polysulfate sodium capsules (Elmiron®) for bladder pain syndrome – the DPC supports prescribing in line with NICE TA610. The committee recommends adding to formularies as RED.

Dapagliflozin tablets (Forxiga®) for use with Insulin for treating people with type 1 diabetes – the Committee supports prescribing in line with NICE TA 597. Prescribing should be recommended by a specialist therefore the Committee suggests adding to formularies as AMBER for this indication.

Other Information and formulary updates

Prucalopride shared care guidelines for treatment of chronic idiopathic constipation have been updated following the discontinuation of lubiprostone and will be available on the website below.

Antacid and Oxetacaine oral suspension - The committee supports changing formulary status of this unlicensed special from RED to AMBER for use with specialist recommendation in patients with oral mucositis/oesophageal lesions and painful swallowing following cancer treatment.

Guidance documents are available [Here](#) (hosted by West Hampshire CCG)

Summarised on behalf of the District Prescribing Committee by Andrea White (Southampton City CCG)